NextGen Bio
Filter News
Found 7,307 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Visus Therapeutics Appoints World-Renowned Ophthalmologist, Eric D. Donnenfeld, M.D., to Board of Directors
1/11/2023
Visus Therapeutics Inc. today announced the appointment of Eric D. Donnenfeld, M.D., to the Company’s Board of Directors.
-
Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer
1/6/2023
Intergalactic Therapeutics, a company focused on transforming medicine through non-viral gene therapy, announced the appointment of Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer.
-
Simnova and Orna Therapeutics Collaborate to Advance Orna's Next Generation Circular RNA Technology in China
1/5/2023
Shanghai Xianbo Biotech Co., Ltd. and BiTE-armed CAR-T cell therapies, and Orna Therapeutics today announced a collaboration agreement to discover, develop, and commercialize multiple potential therapeutics in the area of oncology.
-
LEXEO Therapeutics Appoints Micah Zajic as Chief Financial Officer and Paula H. J. Cholmondeley as Board of Directors Audit Committee Chair
1/5/2023
LEXEO Therapeutics, Inc. today announced the expansion of its leadership team, with the appointment of Micah Zajic as Chief Financial Officer and Paula H.J. Cholmondeley to its Board of Directors as Audit Committee Chair.
-
Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline
1/5/2023
Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, today announced the close of a Series B extension financing, co-led by Novo Holdings A/S, Catalio Capital Management and SymBiosis, with participation from new and existing investors.
-
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
-
Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Prime Medicine, Inc. announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 8:15 a.m. PT in San Francisco, CA.
-
Metagenomi to Present at 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Metagenomi today announced that Brian C. Thomas, Ph.D., Chief Executive Officer and Founder of Metagenomi, will present a company overview at 11:00 a.m. PT on Monday, January 9, 2023 at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA.
-
LEXEO Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
LEXEO Therapeutics, Inc. today announced that R. Nolan Townsend, Chief Executive Officer of LEXEO Therapeutics, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 10:30 AM PT.
-
SomaLogic to Participate in the 41st Annual J.P. Morgan Healthcare Conference
12/29/2022
SomaLogic, Inc., a leader in proteomics technology, announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.
-
Enveda Biosciences Closes $68-million Combined Series B Equity and Debt Financing
12/21/2022
Dimension led the round with multiple new institutional investors and significant participation from current investors; Silicon Valley Bank provided the debt facility.
-
FonesLife offers the 7,000-plex SomaScan® Platform as Japan’s first SomaLogic™ Certified Site
12/19/2022
SomaLogic, Inc., a leader in proteomic technology, announced that Tokyo-based FonesLife Corporation, will be the first SomaLogic™ Certified Site in Japan.
-
Xilis Announces Formation of its Scientific Advisory Board
12/15/2022
Xilis today announced the addition of four members to its newly formed Scientific Advisory Board (SAB).
-
Metagenomi Announces Publication of Data in Nature Communications Describing Novel, Ultra-Small Nucleases for Gene Editing
12/15/2022
Metagenomi Announces Publication of Data in Nature Communications Describing Novel, Ultra-Small Nucleases for Gene Editing.
-
Umoja Biopharma Appoints Dieter Weinand as the Chair of its Board of Directors
12/14/2022
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies, announced the appointment of Dieter Weinand to its Board of Directors where he will take on the role of Chair, effective November 17, 2022.
-
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting
12/11/2022
Graphite Bio, Inc. presented preclinical results supporting the use of a single-cell RNA sequencing method to assess gene correction outcomes in patients treated with nulabeglogene autogedtemcel, an investigational gene-edited therapy for sickle cell disease.
-
AltruBio Presents New Positive Data from its Completed Phase 1b Study Evaluating ALTB-168 in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022
12/10/2022
AltruBio Inc. announced the presentation of new data from its completed Phase 1b clinical trial evaluating ALTB-168 in patients with steroid-refractory or treatment-refractory acute graft-versus-host-disease at the 64th American Society of Hematology Annual Meeting, taking place December 10-13, 2022 in New Orleans, La.
-
Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3Kα Inhibitor at San Antonio Breast Cancer Symposium
12/8/2022
Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3K α Inhibitor at San Antonio Breast Cancer Symposium.